Engineered immune cells take aim at Hard-to-Treat multiple myeloma
NCT ID NCT03455972
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving patients with high-risk multiple myeloma specially engineered T-cells (CAR T-cells) after a stem cell transplant can safely improve outcomes. The T-cells are designed to target two proteins on myeloma cells, CD19 and BCMA. Researchers are monitoring side effects and how long the cancer stays under control in 43 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anti-CD19 and anti-BCMA CAR T-cells
- What this could lead to
- If successful, this could offer a more effective way to control high-risk multiple myeloma after a stem cell transplant, potentially extending remission and survival.
- What could go wrong
- This is an early-phase trial with only 43 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital, Soochow University
Suzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.